The National Institutes of Health today announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia.

NIH’s Accelerating Medicines Partnership program will administer AMP Schizophrenia to leverage resources and expertise from NIH, the Food and Drug Administration and multiple non-profit and private organizations. Their goal is to identify promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other outcomes, and define targets for treatment development.

The initiative also will seek to develop measures that further define early stages of risk while predicting the likelihood of progression to psychosis and other outcomes.

 

Related News Articles

Headline
The AHA and Aligning for Health Sept. 24 hosted a webinar detailing how hospitals and health systems are working to better identify and address health, social…
Headline
Use of primary and preventive care services have declined sharply among children in Medicaid and the Children’s Health Insurance Program since the COVID-19…
Headline
U.S. adults between the ages of 19-22 who reported vaping nicotine and marijuana in 2019 did so in numbers that represent the largest increase in 45 years of…
Blog
Americans everywhere have watched with increasing dismay and alarm as 94 major wildfires continue to incinerate wide swaths of our beautiful Western states. As…
Chairperson's File
Flu season soon will be upon us. And this year, it will take place in the middle of our ongoing battle against COVID-19. The good news is the same essential…
Headline
The numbers of Americans aware of their high blood pressure conditions dropped over a four-year period, from 85% in 2013-2014 to 77% in 2017-2018, according to…